Neurvati Neurosciences’ Post

Intra-Cellular Therapies edges closer to FDA win for #Caplyta in #depression: Intra-Cellular Therapies has secured another win with positive topline results from a Phase III study evaluating Caplyta (lumateperone) as an adjunctive therapy in patients with major depressive disorder (MDD). In the trial, dubbed Study 502 (NCT05061706), a 42mg daily dose of Caplyta (#lumateperone) as an adjunctive therapy provided a 4.5-point reduction on the Montgomery-Asberg Depression Rating Scale (#MADRS) at week 6 compared to placebo, meaning the trial met its primary endpoint. The drug also met the key secondary endpoint of change from baseline on the Clinical Global Impression Scale for Severity of Illness (CGI-S) at week 6. https://lnkd.in/gJHRHVaQ

Our oils support a titration model, allowing for gradual dose increases until optimal therapeutic effects are achieved. This method is particularly valuable in managing conditions such as chronic pain, anxiety and epilepsy, where precise dosing can significantly impact outcomes. Discover the full range at https://lnkd.in/eBVFZMDH Read full article 📖 https://lnkd.in/eXZcmMwD #Titration #MedicalCannabis #CannabisPatient #Clinics

📣 Initial positive results from our client Transcend Therapeutics are out! Methylone, which is a non-hallucinogenic neuroplastogen, produced rapid and durable effects in an open-label study of 14 participants with PTSD symptoms. 6 of these patients were recruited and dosed at our site in London - it was a privilege to see the improving wellbeing of these patients firsthand. 👉 Summary of results: Rapid: Almost 4 in 10 people achieved remission by day 10. Durable: By the end of the study, over 6 in 10 people achieved remission. No SAEs: No drug-related severe adverse effects (SAEs) occurred. A huge congratulations to everyone involved! We look forward to delivering the second part of this study. #methylone #clinicaltrials #clinicalstrial #drugdevelopment #ptsd #mentalhealth

Guillain–Barré syndrome (GBS) is an acute onset, usually monophasic immune-mediated disorder of the peripheral nervous system. The reported incidence rates for GBS are 1–2 per 100,000 population. The lifetime likelihood of any individual acquiring GBS is 1:1000. In Europe and North America AIDP is dominant contributing to 90% of the cases. In contrast in China and Japan AMAN being the most common subtype. Immunotherapy definitely makes a difference in the recovery. of GBS patients and both PE and IVIg are equally effective. IVIg may be preferred because of its low side-effect profile and ease of administration. However, small volume PE can be used with equal efficacy due to cost constraints

Cont. of the effects of Benzos: -There is no such thing as a “baby dose” of a benzo. 1 mg of Xanax = to 20 mg of Valium. 1 mg of Ativan = to 10 mg of Valium. “Baby dose” was a term pushed by the big pharma marketing against Valium dose, which Drs picked up. -According to Yale, 130M Americans are prescribed Benzos and studies show that 80-100% of people will experience benzo WD effects. 1 in 6 will suffer from BIND leaving them possibly disabled & fighting for their life. -Benzo WD & BIND sits on a LARGE spectrum: from anxiety, insomnia, panic attacks, itching, depression -TO- seizures, akathisia, hallucinations, occipital neuralgia, electrocutions, neuropathy, vertigo, hormone receptor damage, loss of mobility, pseudo dementia, POTS, “benzo belly”, lung suppression, agoraphobia, monophobia, DP/DR, mania, suicidal ideation, depression, PTSD, death, & 100’s more symptoms.  -“Kindling” is a phenomenon when a user discontinues their Benzo (or rapid taper) & then goes back onto a benzo. This increases odds of getting BIND. -Interdose intolerance often occurs during Benzo use. Which refers to Benzo WD symptoms in btw doses. Unfortunately, this is commonly misdiagnosed w/ other psychiatric illnesses & doctors tend to polydrug a patient. -Benzos use, interdose, WD & BIND can lead to suicide. -In the US we cannot open a class-act lawsuit against generic pharmaceutical companies, this came after a class-act lawsuit against Benozs in the UK -The gov has not done more on this matter due to pharmaceutical lobbyists, similar to the Opioid crisis.   -Drs NEED to continue prescribing Benzos to patients who are already on it, due to the dangers of cold-turkey & rapid taper.  -Due to benzo education, lawsuits are being made & won. There are EGG scans that show brain damage, expert psychiatrist witnesses & the FDA black boxed warning has helped win cases. Due to the lack of medical education- many are commonly misdiagnosed w/ one or multiple of the following: MS, ASL, Parkinson’s, Fibromyalgia, Trigeminal Neuralgia, Lupus, Lyme, Nerve Damage, Schizophrenia, Bipolar, Multiple Personality Disorder, Manic, etc. Benzos can mimic some to all of these illnesses at the same time. ALL people will heal from benzo WD and BIND, but no one can give a timeline. It can take months to several years. The brain needs time to heal from the synthetic damage. When I was first put on benzos I thought they were a miracle drug, like many, but soon enough they would be the thing trying to take my life. The protocols & help I got as a last resort were the things that actually helped me on all fronts, not the “medicine” that was pushed on me by very uneducated Drs. Please take back reverence. Do your own research when diagnosed or prescribed. Get a second or third opinion. See other types of Drs like Functional, Homeopathic or a Shamen. Benzo Information Coalition: Benzoinfo.com Benzo Support Resources: https://lnkd.in/ep4DCs4w Benzo Support Forum: Benzobuddies.org

Today is Ehlers-Danlos Syndrome (EDS) Awareness Day! What is EDS? EDS is a group of heritable connective tissue disorders. People with EDS struggle with frequent injuries and chronic pain, among many other systemic symptoms. These treatment plans can be complex and usually require a combination of: 🔸 Analgesic therapeutics 🔸 Physical therapy 🔸 Light touch body work 🔸 Mind-body therapies A patient's perception of pain can be greatly impacted by sources of neuroinflammation. For some people, this might be an autoimmune process. For others, it can be mast cell and histamine reactions. Finding and managing these sources of inflammation can positively impact overall pain scores. 👉 What are your questions about EDS? THINKVIDA.COM #eds #edsawareness #hypermobility #ehlersdanlossyndrome #ehlersdanlossyndromeawareness #functionalmedicine #primarycare #familymedicine #seattlewa #guthealthy #autoimmunehealth #inflammationrelief

Thank you 10 News First for sharing the progress Spinogenix, Inc. has made since last year in completing our Phase 1 #clinicaltrials and now officially kicking off trials in Lou Gehrig’s disease (#als), the type of motor neurone disease #mnd Neale Daniher lives with and calls "The Beast".  Our CEO Stella Sarraf, PhD also announced planning is underway for world first trials of #SPG302 in several Australian states in 2024 to treat patients living with #alzheimersdisease and #schizophrenia. SPG302 is a once-a-day pill designed to regenerate #synapses to reverse declines in cognitive, respiratory and motor functions by restoring neuronal connections regardless of the underlying cause of synapse loss. Synapse loss is associated with a variety of neurological and psychiatric diseases. #neurodegenerativediseases #alzheimers #nevergiveup https://lnkd.in/ga3N_kCm

🎥 NEW VIDEO! In this video, Gail Roboz, physician at Weill Cornell Medicine and Know AML ambassador, addresses concerns around side effects in clinical trials. #KnowAML #AcuteMyeloidLeukemia #leukemia

April was one of my biggest months for The Deprescribing Clinic. I worked with 11 patients + a few relatives 😉 Some highlights: *Resolved hallucinations (caused by pramipexole) *Identified B12 deficiency from chronic PPI use causing neuropathy *Worked with a teenage girl with anxiety and discovered significantly reduced MTHFR function *Worked with a geriatric gentleman who needed his metformin renally dosed, got him a CGM, and started an SGLT2i for CKD #pharmacist #deprescribing #pharmacogenomics

Join our #NeuroForum workshop on 9/10 exploring potential applications of GLP-1R medications in the treatment of central nervous system disorders. Speakers will explore current knowledge and research gaps, evidence of their clinical efficacy, and regulatory challenges in repurposing these drugs for neurodegenerative diseases, substance use disorders, and pain. Learn more and register here: https://ow.ly/wonk50SOZGE #TranslationalMedicine #DrugDevelopment #CNSdisorders #GLP1R